誉衡药业：公司纳入到集采范围的核心产品销量有不同程度的增长

Core Viewpoint - The company is experiencing a decline in sales gross margin, which has dropped to 47.29% in the latest interim report, raising concerns among investors about market share and future profitability [1] Group 1: Sales Performance - The company reported that core products included in the centralized procurement (集采) have seen varying degrees of sales growth, with specific products like Luguaduo Peptide Injection expected to grow nearly 10% in sales for 2024 [1] - The sales of Injection Multivitamins (12) are projected to increase by over 40% in 2024, with a growth of over 20% in sales during the first half of this year [1] Group 2: Future Plans and Strategies - The company has indicated that most of its core self-operated products are now part of the centralized procurement, which is expected to stabilize sales [1] - In addition to existing products, the company is actively promoting new product development in hospitals, which is anticipated to contribute additional revenue and gross margin next year [1] - The company plans to enhance operational management to reduce operating costs or stabilize them at a reasonable level [1]